ELITE PHARMACEUTICALS INC /NV/ financial data

Symbol
ELTP on OTC
Location
Northvale, NJ
Fiscal year end
31 March
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 562 % +100%
Quick Ratio 154 % +64.8%
Debt-to-equity 109 % +82.3%
Return On Equity 28 %
Return On Assets 13.4 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.07B shares +0.58%
Common Stock, Shares, Outstanding 1.07B shares +0.48%
Entity Public Float 323M USD +240%
Common Stock, Value, Issued 1.07M USD +0.48%
Weighted Average Number of Shares Outstanding, Basic 1.07B shares +0.34%
Weighted Average Number of Shares Outstanding, Diluted 1.14B shares +6.86%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 123M USD +72.7%
Cost of Revenue 58.2M USD +47.9%
Research and Development Expense 6.9M USD -4.9%
General and Administrative Expense 12.2M USD +48.8%
Operating Income (Loss) 42.2M USD +189%
Nonoperating Income (Expense) -18.4M USD +13.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 23.7M USD
Income Tax Expense (Benefit) 239K USD
Net Income (Loss) Attributable to Parent 13.9M USD
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.11M USD -9.27%
Accounts Receivable, after Allowance for Credit Loss, Current 40.9M USD +90.6%
Inventory, Net 18.2M USD +28.2%
Assets, Current 85.8M USD +89.4%
Deferred Income Tax Assets, Net 11.8M USD -43.4%
Property, Plant and Equipment, Net 10.1M USD -0.77%
Operating Lease, Right-of-Use Asset 1.77M USD -15.2%
Assets 117M USD +32.9%
Accounts Payable, Current 3.42M USD +72.7%
Employee-related Liabilities, Current 206K USD
Accrued Liabilities, Current 6.15M USD +7.87%
Contract with Customer, Liability, Current 2.22K USD -83.3%
Liabilities, Current 10.7M USD -17%
Contract with Customer, Liability, Noncurrent 2.22K USD -85.7%
Operating Lease, Liability, Noncurrent 1.29M USD -25.7%
Liabilities 55.7M USD +36%
Retained Earnings (Accumulated Deficit) -113M USD +11%
Stockholders' Equity Attributable to Parent 61.6M USD +30.3%
Liabilities and Equity 117M USD +32.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 14.8M USD +370%
Net Cash Provided by (Used in) Financing Activities -4.13M USD -2262%
Net Cash Provided by (Used in) Investing Activities -218K USD +86.9%
Common Stock, Shares Authorized 1.45B shares 0%
Common Stock, Shares, Issued 1.07B shares +0.48%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 10.4M USD +698%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 27.1M USD +171%
Interest Paid, Excluding Capitalized Interest, Operating Activities 159K USD -28.7%
Deferred Tax Assets, Valuation Allowance 2.04M USD
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.12 pure
Deferred Tax Assets, Gross 20.1M USD -17.4%
Operating Lease, Liability 1.8M USD -17%
Depreciation 1.23M USD -7.13%
Payments to Acquire Property, Plant, and Equipment 218K USD -72%
Property, Plant and Equipment, Gross 27.7M USD +4.04%
Operating Lease, Liability, Current 504K USD +19.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 667K USD +7.02%
Lessee, Operating Lease, Liability, to be Paid, Year One 18.9K USD +27.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Income Tax Expense (Benefit) 4.88M USD +26725%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 306K USD -38.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 666K USD +4.58%
Deferred Tax Assets, Operating Loss Carryforwards 10.7M USD -31.3%
Current Income Tax Expense (Benefit) 468K USD +36.4%
Lessee, Operating Lease, Liability, to be Paid, Year Four 440K USD -32.4%
Additional Paid in Capital 174M USD +0.23%
Depreciation, Depletion and Amortization 275K USD +21.1%
Deferred Tax Assets, Net of Valuation Allowance 24.3M USD +1018%
Share-based Payment Arrangement, Expense 225K USD +8.87%
Interest Expense 589K USD -47.1%